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Multiple lines of evidence implicate the basolateral amygdala (BLA) and the noradrenergic (norepinephrine, NE) system in
responding to stressful stimuli such as fear signals, suggesting hyperfunction of both in the development of stress-related
pathologies including anxiety disorders. However, no causative link between elevated NE neurotransmission and BLA hyper-
responsiveness to fear signals has been established to date in humans. To determine whether or not increased noradrenergic
tone enhances BLA responses to fear signals, we used functional magnetic resonance imaging (fMRI) and a strategy of pharma-
cologically potentiating NE neurotransmission in healthy volunteers. 18 subjects were scanned two times on a facial emotion
paradigm and given either a single-dose placebo or 4mg of the selective NE reuptake inhibitor reboxetine 2 h prior to an fMRI
session. We found that reboxetine induced an amygdala response bias towards fear signals that did not exist at placebo baseline.
This pharmacological effect was probabilistically mapped to the BLA. Extrapolation of our data to conditions of traumatic stress
suggests that disinhibited endogenous NE signaling could serve as a crucial etiological contributor to post-traumatic stress
disorder (PTSD) by eliciting exaggerated BLA responses to fear signals.
Keywords: amygdala; emotion; face; fear; fMRI; noradrenaline; reboxetine
INTRODUCTION
A capacity to perceive, assesses, control, and adequately
respond to stress is of adaptive importance. However, when
disproportional in intensity, chronic, or unrelated to genuine
threats, stress may become maladaptive and precipitate
stress-related psychiatric disorders (Millan, 2003). The
amygdala is heavily implicated in stress-related pathologies
such as panic disorder (Shekhar et al., 1999), chronic anxiety
(Shekhar et al., 2005), and post-traumatic stress disorder
(PTSD) (Rauch et al., 1996; 2006). One of the most notable
findings from functional magnetic resonance imaging (fMRI)
studies of anxiety disordered patients is a hyperresponsive-
ness of the amygdala to fear signals (Etkin and Wager, 2007).
Also heavily researched for its role in stress and stress-
related pathologies is the locus coeruleus (LC) (Sved et al.,
2002), a collection of 16,000 neurons (per hemisphere)
located in the dorso-rostral pons (Aston-Jones and Cohen,
2005a, 2005b; Berridge and Waterhouse, 2003). The
basolateral complex of the amygdala (BLA) receives a
dense noradrenergic (norepinephrine, NE) innervation
from the LC (Asan, 1998), and NE levels increase in the
BLA with exposure to stressful stimuli (Galvez et al., 1996;
Hatfield et al., 1999). Neurons in the LC are activated by
stressful stimuli (Abercrombie and Jacobs, 1987) and med-
iate the stress-induced enhancement of NE neurotransmis-
sion in the BLA (Buffalari and Grace, 2007).
Although prefrontal cortex (PFC) subregions have been
shown to exert top-down inhibitory control over the stress
response, leading to dampening of response to stressful
stimuli (Amat et al., 2005), the BLA and LC appear to reci-
procally interact in promoting the stress response, which
implicates the disinhibition of both in the development
of maladaptive stress responses and anxiety disorders
(Buffalari and Grace, 2007). There is indeed substantial clin-
ical evidence for a crucial role of LC-NE overdrive as an
important neurochemical substrate of – and thereby obvious
therapeutic target in – PTSD (Southwick et al., 1993; 1997).
b-adrenergic blockade of LC-NE signaling with propranolol
attenuates symptoms of anxiety (Granville-Grossman and
Turner, 1966) and appears to be effective in the secondary
prevention of PTSD (Pitman et al., 2002; Vaiva et al., 2003).
However, no causative link between elevated NE neurotrans-
mission and BLA hyperresponsiveness to fear signals has
been established to date in humans.
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To determine whether or not such functional bias
emerges under conditions of elevated BLA noradrenergic
activity, we used a strategy of pharmacologically potentiat-
ing NE neurotransmission in healthy volunteers. Eighteen
subjects participated in a double-blind, placebo-controlled,
randomized fMRI study. Subjects underwent imaging
two times (at least a week apart) and were administered
either a single-dose placebo or 4 mg of the selective NE
reuptake inhibitor reboxetine. We used ecologically valid
dynamic facial expressions to stimulate the amygdala
(van der Gaag et al., 2007), and cytoarchitectonic maxi-
mum probabilistic maps of amygdala subregions (Amunts
et al., 2005; Eickhoff et al., 2005) to determine suscept-




Eighteen healthy adults (nine females, nine males; mean age,
24 years; age range, 19–33 years) volunteered after giving
written, informed consent. The study had full ethical
approval and was accomplished in compliance with the
latest revision of the Declaration of Helsinki. All volunteers
were right-handed, as assessed by the Edinburgh Handedness
Inventory (Oldfield, 1971). Subjects were screened for MRI
compatibility and determined to be free of current or past
medical, neurological, or psychiatric illness, drug/alcohol
abuse, and psychoactive medication. Psychiatric assessment
included the BDI (Beck Depression Inventory) (Beck et al.,
1995) and the M.I.N.I. (Mini International Neuropsychiatric
Interview) (Lecrubier et al., 1997). Neuropsychological
assessment included a measure of verbal IQ based on lexical
decisions (MWTB, Mehrfachwahl-Wortschatz-Test) (Lehrl,
1995) and a test of facial emotion recognition (FEEST, Facial
Expressions of Emotions: Stimuli and Test) (Young et al.,
2002). In brief, subjects had neither neuropsychological
impairments nor any psychopathology. In addition, heart
rate, blood pressure, and an electrocardiogram (ECG) were
obtained from each subject to exclude any cardiovascular
abnormalities.
Study design
The rationale of the present study was to potentiate NE
neurotransmission in healthy volunteers in order to phar-
macologically model an amygdala response bias towards fear.
In a within-subjects, double-blind study design, subjects
received one tablet of reboxetine mesilate (4 mg) or saccharose
placebo two hours prior to an fMRI session. This interval was
chosen because maximum reboxetine serum concentrations
in humans are usually reached two hours after oral intake
(serum half-life, 13 h) (Fleishaker, 2000). The order of drug/
placebo administration was counterbalanced across subjects.
Reboxetine is a highly selective inhibitor of presynaptic NE
reuptake and thus increases synaptic availability of NE
(Kent, 2000; Scates and Doraiswamy, 2000). A 4-mg single
oral dose of reboxetine was administered in analogy to
previous studies investigating noradrenergic modulation of
emotional and cognitive functions and their interactions
(Hurlemann et al., 2005, 2007; Norbury et al., 2007; Papps
et al., 2002). Heart rate and blood pressure were measured
once before drug administration and once before fMRI
scanning. In addition, a venous blood sample was collected
after fMRI scanning. The resulting reboxetine serum levels
were as follows: mean, 123.1 ng/ml; SD, 37.3 ng/ml (for a
detailed synopsis of analytical procedures see Hurlemann
et al., 2007).
FMRI paradigm
The fMRI paradigm consisted of a pseudorandom series of
movies obtained from 10 professional actors (five females,
five males) who in each clip displayed either a fearful,
neutral, or happy facial expression in a standardized fashion
(for a detailed description of stimuli see van der Gaag et al.,
2007). In the emotionally neutral movies, actors blew up
their cheeks, which served to control for facial movements
in happy and fearful stimuli (Figure 1A). In previous fMRI
studies, happy, fearful, and neutral movies produced equally
robust amygdala responses (van der Gaag et al., 2007),
making these stimuli an ideal imaging probe to study a
pharmacologically induced response bias in the amygdala.
Moreover, we used dynamic instead of static stimuli for
higher ecological validity: in everyday life, during social
interactions, dynamic facial expressions rather than static
facial displays serve as the primary conveyors of social-
emotional information (see also Hurlemann et al., 2008).
We thereby adapted an approach also used in recent
single-neuron recording studies of the primate amygdala;
this approach accounts for the fact that primates never see
static facial displays in their natural environment (Kuraoka
and Nakamura, 2007). Each movie had duration of 3 s and
was repeated two times, resulting in 30 stimulus presenta-
tions per condition. Movies occurred at a rate of one every
13.2 s (7.8–18.6 s) over a period of 20 min. A fixation cross
was interspersed between each movie. During fMRI scan-
ning, subjects were engaged in a gender judgment task
requiring appropriate push-button responses. Stimulus
delivery and response recording was carried out using
Presentation12 (Neurobehavioral Systems, Inc., Albany,
CA, USA).
Data acquisition
An Avanto MRI system (Siemens, Erlangen, Germany) oper-
ating at 1.5T was used to obtain T2*-weighted echoplanar
(EPI) images with blood-oxygen-level-dependent (BOLD)
contrast (TR¼ 2.70 s, TE¼ 40 ms, matrix size: 64 64,
pixel size: 3 3 mm2, slice thickness¼ 1.8 mm, distance
factor¼ 50%, FoV¼ 192 mm, flip angle¼ 888, 39 axial
slices) with the parallel acquisition technique generalized
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autocalibrating partially parallel acquisitions (GRAPPA).
Based on the a priori hypothesis the 39 slices were oriented
centrally to the amygdala. Five hundred and fifty volumes
were acquired; the first five volumes were discarded to
allow for T1 equilibration effects. Stimuli were presented
with liquid crystal display video goggles. In addition,
high-resolution anatomical MRI images were acquired
(T1 weighted 3D MPRAGE).
Data analysis
The image preprocessing was performed using Matlab7
(The MathWorks, Inc., Natick, MA, USA) and SPM5
(http://www.fil.ion.ucl.ac.uk/spm). The EPI images were
corrected for head movement between scans by an affine
registration (Ashburner and Friston, 2003). For realignment
we used a two-pass procedure, by which images were initially
realigned to the first image of the time-series and sub-
sequently re-realigned to the mean of all images after the
first step. After completing the realignment, the mean EPI
image for each subject was computed and spatially normal-
ized to the MNI template (Collins et al., 1994; Evans et al.,
1992; Holmes et al., 1998) using the "unified segmentation"
function in SPM5. This algorithm is based on a probabilistic
framework that enables image registration, tissue classifi-
cation, and bias correction to be combined within the
same generative model. The resulting parameters of a dis-
crete cosine transform, which define the deformation field
necessary to move the subjects’ data into the space of the
MNI tissue probability maps (Evans et al., 1994), were then
combined with the deformation field transforming between
the latter and the MNI single subject template. The ensuing
deformation was subsequently applied to the individual EPI
volumes. All images were hereby transformed into standard
stereotaxic space and resampled at 2 2 2 mm3 voxel size.
The normalized images were spatially smoothed using an
8 mm FWHM Gaussian kernel.
The three conditions were modeled by means of reference
waveforms which correspond to stick functions placed at
the onset of the stimuli convolved with a hemodynamic
response function (Friston et al., 1995). A design matrix
comprising contrasts of alternating intervals of the different
trials, the time derivative, and movement parameters was
created. Specific effects were assessed by applying appro-
priate linear contrasts to the parameter estimates of the
experimental trials resulting in t-statistics for each voxel.
These formed Statistical Parametric Maps (SPM{T}) of dif-
ferences between the conditions. SPM{T}-statistics were
interpreted in light of the theory of probabilistic behavior
of Gaussian random fields.
Drug-specific effects on brain activation associated with
the three experimental conditions were assessed by a second
level analysis constituting a random effects model. For each
simple effect of any of the three fMRI sessions, individual
contrast images of each subject were entered into a second
level analysis based on an Analysis of Variance (repeated
measures ANOVA).
For a hypothesis-driven analysis, the left and right
amygdala – including their basolateral, centromedial, and
superficial subregions – were defined as regions-of-interests
(ROIs) based on cytoarchitectonic maximum probability
maps derived from histological analysis of 10 human
post-mortem brains (Amunts et al., 2005; Eickhoff et al.,
2005). The feasibility of this probabilistic approach has
been demonstrated in previous fMRI studies (Ball et al.,
2007; Hurlemann et al., 2008). The a priori focus on
hypothesized areas serves to prevent false-positive findings
(Stein et al., 1998). Thus, the current study used primarily
a ROI approach.
RESULTS
Driven by our a priori hypothesis, we performed a ROI-
analysis focused on the left and right amygdala. Reboxetine
enhanced the difference between right BLA responses to
fearful vs neutral stimuli [MNI-coordinates xyz¼ 28, 4,
–29, P< 0.001, uncorrected; P¼ 0.07, family-wise error
(FWE)-corrected]. This enhancement was driven by an
increased activation to fearful stimuli and by a decreased
activation to neutral stimuli (Figure 1A). The opposite
contrast did not reveal any significant effect of reboxetine.
The observation that enhancement of right BLA responses
to fearful vs neutral stimuli was restricted to the reboxetine
fMRI session and absent in the placebo fMRI session,
indicates that this effect is pharmacologically induced
(Figure 1A).
One important consideration in this context is the dif-
ferentiation between reboxetine effects on neural tissue or
on the BOLD response. To exclude any effect of reboxetine
on global neural activation based on changes in baseline
cerebral blood flow or neural coupling, we analyzed the
relative signal change profile in the primary visual cortex
(area V1). Specifically, we determined the relative signal
change profile from the onset of the stimuli to the end of
the hemodynamic response function (for a similar approach
see Miskowiak et al., 2007; Paulus et al., 2005). This analysis
revealed that reboxetine left the amplitudes as well as the
latencies of minima and maxima of the V1 hemodynamic
response function unchanged. Comparison of standard
deviations did not reveal any significant differences either
(Figure 1B). These results indicate that the effects of rebox-
etine reflect regionally specific pharmacological modulation
of neural responses.
Extending our analysis of reboxetine effects to the whole
brain (P< 0.001, uncorrected; voxel extent threshold >5),
we identified increased activations of the right amygdala,
right hippocampus, right Heschl’s gyrus, inferior frontal
gyrus (bilateral), fusiform gyrus (bilateral), and higher-
order visual cortical areas when contrasting the fearful
with the neutral condition. Reboxetine decreased responses
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in the left hippocampus, left middle occipital gyrus, and
cerebellum. The contrast between the happy and the neutral
condition identified increased activations of the left caudate
nucleus, left insula, left superior medial frontal gyrus, cingu-
late gyrus, cerebellum, and higher-order visual cortical areas,
whereas responses in the left superior orbital frontal gyrus,
right inferior temporal gyrus, and right calcarine gyrus were
decreased by reboxetine. Regional activations are listed in
Tables 1 and 2.
DISCUSSION
We used a strategy of pharmacologically potentiating NE
neurotransmission in healthy volunteers to demonstrate an
enhanced difference between right BLA responses to fearful
vs neutral stimuli under conditions of increased noradrener-
gic tone. Specifically, a hyperresponsiveness to fearful stimuli
was coupled with a hyporesponsiveness to neutral stimuli.
This shift in BLA response characteristics was pharmacol-
ogically induced.
Fig 1 (A) Activation map resulting from the fearful-minus-neutral contrast in a ROI analysis of the amygdala (i) Probabilistic mapping demonstrates increased differential activity
in the right BLA (MNI-coordinates X, Y, Z¼ 28, 4, 29). (ii) Plotted are the relative signal changes in the BOLD response of the activated voxels for the two fMRI sessions
(reboxetine, placebo) and the three experimental conditions (fearful, happy, neutral) relative to the mean of the global signal. Potentiation of NE neurotransmission with
reboxetine increased BLA responses to fearful stimuli and decreased BLA responses to neutral stimuli. This effect was pharmacologically induced. BLA responses to fearful, happy
or neutral stimuli did not significantly differ from each other at placebo baseline. (B) Relative signal changes in the BOLD response of activated clusters within the primary visual
cortex (V1). Amplitudes and latencies of minima and maxima of the V1 hemodynamic response profile were not affected by the reboxetine challenge, which argues against
a global homogeneous drug effect on the BOLD signal. Error bars indicate SEM. Abbreviations: BLA, basolateral complex of the amygdala; EC, entorhinal cortex; L, left hemisphere;
P, posterior; PLC, placebo; R, right hemisphere; RBX, reboxetine; SUB, subiculum.
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Notably, the pharmacological challenge had no effect
on neural responses in the primary visual cortex, arguing
against a global homogeneous drug effect on the BOLD
signal. Moreover, this study is the first to probabilistically
map a single-dose effect of reboxetine to the BLA. This result
is in keeping with studies in rodents that demonstrated
susceptibility of BLA function to pharmacological manipula-
tions of NE signaling (McGaugh, 2000).
Our finding that pharmacological enhancement of BLA
noradrenergic activity is required to induce a response bias
towards fear conflicts with concepts of the amygdala as a
neural module with an intrinsic fear selectivity (Phan
et al., 2002). However, fMRI studies that used movies of
facial expressions instead of static photographs to stimulate
the amygdala under more ecological conditions found no
differences between amygdala responses to fearful, neutral,
or happy facial expressions (van der Gaag et al., 2007).
Similar results were obtained within the chemosensory
(Anderson et al., 2003; Small et al., 2003) and cognitive
domains (Hamann et al., 1999; Hurlemann et al., 2005)
Table 1 List of brain regions showing a significant interaction effect of condition (fearful/happy vs neutral facial expressions) and drug (reboxetine vs placebo)
(P< 0.001, uncorrected; voxel extent threshold >5)
Contrast Region Side k MNI-coordinates T
x y z
(Fear > Neutral) Reboxetine> (Fear > Neutral) Placebo
Heschl’s gyrus R 33 50 16 8 4.16
Inferior frontal gyrus R 33 42 42 10 3.97
Fusiform gyrus R 26 32 60 14 3.87
Precuneus R 26 20 54 44 3.85
Lingual gyrus R 22 18 86 4 3.89
Fusiform gyrus L 15 36 56 8 3.91
Inferior frontal gyrus L 13 –22 30 12 3.71
Angular gyrus R 12 54 50 30 3.65
Supramarginal gyrus L 11 48 44 32 3.63
Hippocampus/Amygdala R 8 26 6 32 3.27
Supramarginal gyrus R 7 60 24 22 3.56
(Happy > Neutral) Reboxetine> (Happy > Neutral) Placebo
Supramarginal gyrus L 42 46 40 30 3.66
Caudate nucleus L 38 18 4 26 4.11
Cerebellum R 33 16 64 34 3.96
Rectal gyrus R 27 14 28 20 4.60
Superior medial frontal gyrus L 23 12 38 28 3.76
Superior medial frontal gyrus L 20 8 48 6 3.70
Middle cingulum R 12 12 16 34 3.94
Middle occipital L 10 32 74 14 3.47
Precuneus R 8 12 56 42 3.40
Insula L 6 28 14 10 3.34
Middle occipital L 6 28 86 42 3.33
Cerebellar vermis R 6 4 68 20 3.32
Table 2 List of brain regions showing a significant interaction effect of condition (fearful/happy vs neutral facial expressions) and drug (placebo vs reboxetine)
(P< 0.001, uncorrected; voxel extent threshold >5)
Contrast Region Side k MNI-coordinates T
x y z
(Fear > Neutral) Placebo> (Fear > Neutral) Reboxetine
Middle occipital gyrus L 29 40 74 24 3.86
Whitte matter L 9 26 14 16 3.55
Hippocampus L 7 12 28 6 3.55
Cerebellum R 6 56 58 34 3.54
(Happy > Neutral) Placebo> (Happy > Neutral) Reboxetine
Inferior temporal gyrus R 32 48 56 16 4.29
Superior orbital frontal gyrus L 20 18 54 10 3.91
Calcarine gyrus R 7 18 44 6 3.29
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when appetitive and aversive stimuli were matched for
intensity (arousal). Thus, from our findings it appears that
stress-induced increases in NE signaling act to convert
a subset of BLA neurons into a fear module, perhaps
by selectively augmenting the signal-to-noise ratio for
fearful information at the cost of neutral information.
One scenario would be that those neurons that are potently
activated by NE project to downstream BLA targets mediat-
ing fear-related behavioral responses (Buffalari and Grace,
2007).
Extrapolation of our results to conditions of traumatic
stress suggests that disinhibited LC-NE signaling could
serve as a crucial etiological contributor to the onset and
maintenance of PTSD by eliciting exaggerated BLA responses
to the traumatic stressor. Several lines of evidence suggest
that the degree of top-down inhibitory control orchestrated
by the medial PFC (mPFC) is the variable that ultimately
determines the magnitude of the endogenous stress response
(Arnsten and Goldman-Rakic, 1984; Aston-Jones and
Cohen, 2005a, 2005b; Berridge and Waterhouse, 2003;
Jodo et al., 1998; Kim and Diamond, 2002; Robbins,
2005). Seminal findings in rodents indicate that, when a
stressor is controllable, activation of autonomic nuclei is
inhibited by descending connections from mPFC, and the
behavioral sequelae of uncontrollable stress are blocked; in
turn, experimental inactivation of mPFC eliminates stressor
controllability and evokes maladaptive stress responses
(Amat et al., 2005). Given this empirical background, we
suggest that disinhibited LC-NE bottom-up signaling is
responsible for exaggerated amygdala responses to fear
signals, leading to excessive acquisition of conditioned fear
responses (Rauch et al., 2006) as well as overlearning and
overconsolidation of traumatic memories (Hurlemann,
2008). We thus speculate that the efficacy of propranolol in
the secondary prevention of PTSD (Pitman et al., 2002;
Vaiva et al., 2003) relies to a considerable extent on a
normalization of BLA hyperfunction by attenuating the
detrimental effects of disinhibited LC-NE input.
Our results contrast with fMRI studies where a daily 4-mg
dose of reboxetine was administered to healthy volunteers
over a one-week period to establish a positive response
bias in the amygdala, evident in decreased amygdala
responses to fearful faces and increased amygdala responses
to happy faces (Norbury et al., 2007). These changes in
the amygdala response profile would be consistent with an
antidepressive effect of reboxetine in patient populations
undergoing (sub)chronic treatment with this agent
(Burrows et al., 1998). However, experiments in rodents
demonstrate that the response to reboxetine varies sub-
stantially as a function of treatment duration. According
to these experiments, single-dose reboxetine increased
anxiety-related behaviors, whereas subchronic administra-
tion of reboxetine over a one-week period decreased
anxiety-related behaviors (Inoue et al., 2006; see also
Miyata et al., 2007). These results may reconcile discrepant
observations derived from single-dose and (sub)chronic
administrations of reboxetine. In this context, we note that
reboxetine treatment has been reported to provoke symptom
exacerbation in patients with borderline personality disorder
(Anghelescu et al., 2005), underscoring the potential risks
associated with acute elevations of NE signaling in patient
populations, a finding that definitely merits further
investigation.
One limitation of the present study is the relatively low
field strength of the MRI system (1.5T), which complicates
the probabilistic assignment of activation sites to micro-
anatomically defined amygdala subregions. To account for
the short distances between these subregions, we used
a rather narrow slice thickness of 1.8 mm (pixel size,
3 3 mm2). Nevertheless, the accuracy of probabilistic map-
ping could be further improved by using MRI systems with
field strengths of 3T or higher and a slice thickness of 1 mm
or less.
Conclusions: We used pharmacological fMRI to model
a BLA response bias towards fear signals. This model
might help to advance our understanding of how stress-
evoked escalations in LC-NE signaling could distort BLA
function and thus predispose to stress-related pathologies
including anxiety disorders.
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